These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 15027511)

  • 1. Design and analytic considerations for single-armed studies with misclassification of a repeated binary outcome.
    Lyles RH; Lin HM; Williamson JM
    J Biopharm Stat; 2004 Feb; 14(1):229-47. PubMed ID: 15027511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of the intervention effect in a non-randomized study with pre- and post-mismeasured binary responses.
    Lin HM; Lyles RH; Williamson JM; Kunselman AR
    Stat Med; 2005 Feb; 24(3):419-35. PubMed ID: 15543548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extending McNemar's test: estimation and inference when paired binary outcome data are misclassified.
    Lyles RH; Williamson JM; Lin HM; Heilig CM
    Biometrics; 2005 Mar; 61(1):287-94. PubMed ID: 15737105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction of confounding bias in non-randomized studies by appropriate weighting.
    Schmoor C; Gall C; Stampf S; Graf E
    Biom J; 2011 Mar; 53(2):369-87. PubMed ID: 21308726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Robustness of an odds-ratio test in a stratified group sequential trial with a binary outcome measure.
    Srivastava DK; Rai SN; Pan J
    Biom J; 2007 Jun; 49(3):351-64. PubMed ID: 17623341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sample size determination in step-up testing procedures for multiple comparisons with a control.
    Kwong KS; Cheung SH; Wen MJ
    Stat Med; 2010 Nov; 29(26):2743-56. PubMed ID: 20799258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian estimation of intervention effect with pre- and post-misclassified binomial data.
    Stamey JD; Seaman JW; Young DM
    J Biopharm Stat; 2007; 17(1):93-108. PubMed ID: 17219757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical analysis for two-stage seamless design with different study endpoints.
    Chow SC; Lu Q; Tse SK
    J Biopharm Stat; 2007; 17(6):1163-76. PubMed ID: 18027223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On design considerations and randomization-based inference for community intervention trials.
    Gail MH; Mark SD; Carroll RJ; Green SB; Pee D
    Stat Med; 1996 Jun; 15(11):1069-92. PubMed ID: 8804140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A likelihood-based, counterfactual approach to accounting for treatment failures in clinical trials.
    Shaffer ML; Chinchilli VM
    J Biopharm Stat; 2003 Aug; 13(3):481-94. PubMed ID: 12921395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptive designs for dose-finding studies based on sigmoid Emax model.
    Dragalin V; Hsuan F; Padmanabhan SK
    J Biopharm Stat; 2007; 17(6):1051-70. PubMed ID: 18027216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A confidence interval for the ratio of treatment variances in a two-by-two crossover study.
    Bristol DR
    J Biopharm Stat; 1991; 1(2):237-45. PubMed ID: 1844699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On tests of equivalence via non-unity relative risk for matched-pair design.
    Tang NS; Tang ML; Chan IS
    Stat Med; 2003 Apr; 22(8):1217-33. PubMed ID: 12687652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Test for the consistency of noninferiority from multiple clinical trials.
    Yan X; Wang MC; Su X
    J Biopharm Stat; 2007; 17(2):265-78. PubMed ID: 17365223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guidelines for measurement validation in clinical trial design.
    Sanchez MM; Binkowitz BS
    J Biopharm Stat; 1999 Aug; 9(3):417-38. PubMed ID: 10473029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal number of repeated measures and group sizes in clinical trials with linearly divergent treatment effects.
    Winkens B; Schouten HJ; van Breukelen GJ; Berger MP
    Contemp Clin Trials; 2006 Feb; 27(1):57-69. PubMed ID: 16260188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials.
    Tamura RN; Huang X
    Clin Trials; 2007; 4(4):309-17. PubMed ID: 17848492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing for treatment effect in the presence of regression toward the mean.
    George V; Johnson WD; Shahane A; Nick TG
    Biometrics; 1997 Mar; 53(1):49-59. PubMed ID: 9147603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of group sequential designs in clinical trials on the basis of detectable treatment differences.
    Schäfer H; Müller HH
    Stat Med; 2004 May; 23(9):1413-24. PubMed ID: 15116350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal designs for clinical trials with second-order polynomial treatment effects.
    Winkens B; Schouten HJ; van Breukelen GJ; Berger MP
    Stat Methods Med Res; 2007 Dec; 16(6):523-37. PubMed ID: 17698939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.